Jim Cramer: The Allergan-Pfizer Deal Is Absolutely Dead
Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said the merger between Pfizer (PFE) - Get Report and Allergan (ACT) - Get Report isn't going anywhere, as lawmakers try to limit corporate inversions. 'We have a position for Action Alerts PLUS, and we have been waiting for it to come down,' Cramer said. 'We didn't think it would come down this much.' He thinks Allergan is a 'screaming buy' below $220 a share.
At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.
